Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

por Jean-Louis Pujol, MD, PhD, Johan Vansteenkiste, MD, PhD, Luis Paz-Ares Rodríguez, MD, PhD, Vanesa Gregorc, MD, Julien Mazieres, MD, PhD, Mark Awad, MD, PhD, Pasi A. Jänne, MD, PhD, Michael Chisamore, PhD, Anwar M. Hossain, MStat, Yanyun Chen, PhD, J. Thaddeus Beck, MD, FACP
Publicado 2021

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

por Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok-Kin Wong, Peter S. Hammerman
Publicado 2016